The source of individual heterogeneity shapes infectious disease outbreaks.

emerging infectious diseases epidemiology evolutionary rescue infection duration modelling superspreading

Journal

Proceedings. Biological sciences
ISSN: 1471-2954
Titre abrégé: Proc Biol Sci
Pays: England
ID NLM: 101245157

Informations de publication

Date de publication:
11 05 2022
Historique:
entrez: 4 5 2022
pubmed: 5 5 2022
medline: 6 5 2022
Statut: ppublish

Résumé

There is known heterogeneity between individuals in infectious disease transmission patterns. The source of this heterogeneity is thought to affect epidemiological dynamics but studies tend not to control for the overall heterogeneity in the number of secondary cases caused by an infection. To explore the role of individual variation in infection duration and transmission rate in parasite emergence and spread, while controlling for this potential bias, we simulate stochastic outbreaks with and without parasite evolution. As expected, heterogeneity in the number of secondary cases decreases the probability of outbreak emergence. Furthermore, for epidemics that do emerge, assuming more realistic infection duration distributions leads to faster outbreaks and higher epidemic peaks. When parasites require adaptive mutations to cause large epidemics, the impact of heterogeneity depends on the underlying evolutionary model. If emergence relies on within-host evolution, decreasing the infection duration variance decreases the probability of emergence. These results underline the importance of accounting for realistic distributions of transmission rates to anticipate the effect of individual heterogeneity on epidemiological dynamics.

Identifiants

pubmed: 35506229
doi: 10.1098/rspb.2022.0232
pmc: PMC9065969
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20220232

Références

Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Science. 2014 Nov 21;346(6212):987-91
pubmed: 25359852
Emerg Infect Dis. 2016 Jun;22(6):1014-21
pubmed: 27191380
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186
Proc Biol Sci. 2006 Sep 22;273(1599):2327-33
pubmed: 16928635
Science. 2021 Feb 5;371(6529):
pubmed: 33303686
Emerg Infect Dis. 2005 Apr;11(4):637-8
pubmed: 15834986
Proc Biol Sci. 2007 Feb 22;274(1609):599-604
pubmed: 17476782
J Math Biol. 2008 Mar;56(3):293-310
pubmed: 17668212
Stat Med. 2005 Aug 30;24(16):2525-37
pubmed: 16013037
Science. 2003 Jun 20;300(5627):1966-70
pubmed: 12766207
Int J Infect Dis. 2016 Feb;43:58-61
pubmed: 26711624
PLoS One. 2012;7(11):e50972
pubmed: 23226436
PLoS Med. 2005 Jul;2(7):e174
pubmed: 16013892
Proc Biol Sci. 2006 Dec 22;273(1605):3075-83
pubmed: 17015347
Theor Popul Biol. 2007 Dec;72(4):576-91
pubmed: 17900643
J R Soc Interface. 2016 Aug;13(121):
pubmed: 27581480
Int J Hyg Environ Health. 2009 Jan;212(1):97-104
pubmed: 18178524
Wellcome Open Res. 2020 Apr 9;5:67
pubmed: 32685698
Am Nat. 2014 Apr;183(4):E105-17
pubmed: 24642501
Theor Popul Biol. 2001 Aug;60(1):59-71
pubmed: 11589638
Proc Biol Sci. 2012 Jun 22;279(1737):2473-8
pubmed: 22357260
J R Soc Interface. 2010 Oct 6;7(51):1455-74
pubmed: 20410190
Epidemiol Infect. 2016 Jun;144(8):1652-60
pubmed: 26808232
Science. 2021 Jan 15;371(6526):
pubmed: 33234698
Emerg Infect Dis. 2004 Feb;10(2):256-60
pubmed: 15030693
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Trends Microbiol. 2011 Jan;19(1):24-32
pubmed: 21055948
Lancet Infect Dis. 2015 Mar;15(3):320-6
pubmed: 25619149
Philos Trans R Soc Lond B Biol Sci. 2013 Feb 04;368(1614):20120333
pubmed: 23382433
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):338-42
pubmed: 8990210
Nature. 2003 Dec 11;426(6967):658-61
pubmed: 14668863
Evolution. 2013 Oct;67(10):2769-82
pubmed: 24094332
Am Nat. 2008 Oct;172(4):E150-68
pubmed: 18702601
Philos Trans R Soc Lond B Biol Sci. 2013 Jan 19;368(1610):20120086
pubmed: 23209168
J Theor Biol. 2008 Jul 21;253(2):228-37
pubmed: 18423673
Emerg Infect Dis. 2004 Apr;10(4):608-14
pubmed: 15200849
Proc Biol Sci. 2015 May 7;282(1806):20150347
pubmed: 25833863
Am J Epidemiol. 1987 Dec;126(6):1082-92
pubmed: 2825518
Lancet Infect Dis. 2015 May;15(5):507-8
pubmed: 25932579
IMA J Math Appl Med Biol. 1989;6(4):233-42
pubmed: 2577998
Proc Biol Sci. 2005 Sep 22;272(1575):1949-56
pubmed: 16191602
Epidemiol Infect. 2007 Oct;135(7):1145-50
pubmed: 17156499
PLoS Pathog. 2007 Mar;3(3):e45
pubmed: 17397261
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17441-6
pubmed: 17954909
Lancet Infect Dis. 2009 May;9(5):291-300
pubmed: 19393959

Auteurs

Baptiste Elie (B)

MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.

Christian Selinger (C)

MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
Swiss Tropical and Public Health Institute, Basel, Kreuzstrasse 2, Allschwil 4123, Switzerland.

Samuel Alizon (S)

MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, Université PSL, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH